Literature DB >> 1772669

Results of resection for bronchogenic carcinoma with mediastinal lymph node metastases in selected patients.

J F Régnard1, P Magdeleinat, D Azoulay, P Dartevelle, M Deneuville, A Rojas-Miranda, P Levasseur.   

Abstract

Between 1982 and 1988, 254 consecutive patients underwent resection for bronchogenic carcinoma with mediastinal lymph node metastases at Marie Lannelongue Hospital. Selection of cases for surgery was carried out using CT and mediastinoscopy. The surgical procedure performed were pneumonectomy (169), lobectomy (65), or bilobectomy (20) associated with resection of ipsilateral mediastinal lymph nodes. Almost all diseased nodes appeared grossly enlarged at surgery and only a few were of normal size. Postoperative mortality was 5.6%. Resection was potentially curative in 191 cases (75%) and palliative in 63 cases (25%). Almost all patients received adjuvant treatment (mainly radiotherapy). Actuarial 5-year survival was 18% for the entire group, and 23% for those who underwent curative resection. No patient with palliative resection survived 5 years. The following factors proved to be significantly associated with a better prognosis: complete resection, independent lymph node metastases, involvement of only one level, lower paratracheal involvement. On the other hand, there was no difference between pathological types (squamous cell carcinomas, adenocarcinomas, oat cell carcinomas) with regard to prognosis. We advocate an aggressive approach in selected cases of N2 bronchogenic carcinoma. Neoadjuvant chemotherapy should be tested in these specific patients with a view to the possibility of improving results.

Entities:  

Mesh:

Year:  1991        PMID: 1772669     DOI: 10.1016/1010-7940(91)90224-8

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.

Authors:  Luigi Moretti; David S Yu; Heidi Chen; David P Carbone; David H Johnson; Vicki L Keedy; Joe B Putnam; Alan B Sandler; Yu Shyr; Bo Lu
Journal:  Oncologist       Date:  2009-11-06

2.  Is invasive mediastinal staging necessary in intermediate risk patients with negative PET/CT?

Authors:  Marc Boada; David Sánchez-Lorente; Alejandra Libreros; Carmen M Lucena; Ramón Marrades; Marcelo Sánchez; Pilar Paredes; Mario Serrano; Angela Guirao; Rudith Guzmán; Núria Viñolas; Francesc Casas; Carles Agustí; Laureano Molins
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

3.  Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).

Authors:  Qianli Ma; Deruo Liu; Yongqing Guo; Bin Shi; Zhiyi Song; Yanchu Tian
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-04

4.  The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.

Authors:  Hongxia Duan; Long Liang; Shuanshuan Xie; Changhui Wang
Journal:  BMC Cancer       Date:  2020-08-26       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.